Site brasileiro onde você pode comprar qualidade e entrega viagra preço cialis barato em todo o mundo.

Microsoft word - cv_degroot_final_20-11-2013.doc

CURRICULUM VITAE
Akademischer Werdegang
Medizinstudium an der Christian-Albrechts-Universität Kiel und der University of Sydney, Australia mit Aufenthalten in Bolton und Manchester, UK sowie Le Mans, Promotion (Mucopolysaccharidosis- & lipidosisartige Veränderungen in kultivierten Corneafibroblasten nach Behandlung mit Tiloronanaloga) Ärztin im Praktikum: Henriettenstiftung Hannover, Germany Wissenschaftliche Mitarbeiterin in der Med. Universität Lübeck und Rheumaklinik Bad Bramstedt (Direktor Prof. Dr. W.L. Gross) Wissenschaftliche Mitarbeiterin in der Abteilung für Nephrologie, Med. Hochschule Hannover (Direktoren: Prof. Dr. Koch und Haller) Habilitationsstipendium der Dorothea-Erxleben-Stiftung Facharztanerkennung Nephrologie, Oberärztin in der Abt. Nephrologie der MHH Habilitation im Fach Innere Medizin (Therapiestrategien bei ANCA-assoziierten Vaskulitiden: Von der empirischen Therapie bis zur prospektiven, kontrollierten, Verleihung des Bruno Schuler Preises durch die DGRh Oberärztin am Zentrum Innere Medizin der MHH für „Zentrale Notaufnahme“ und internistische Aufnahmestation sowie Nephrologie Chefärztin Med. Klinik III (Innere Medizin, Nephrologie und Rheumatologie), Klinikum Ärztliche Leitung im KfH-Nierenzentrum Offenbach Außerplanmäßige Professur für Innere Medizin an der Medizinischen Hochschule Wissenschaftliche Aktivitäten
Entzündliche Gefäß- und Gelenkerkrankungen mit Nierenbeteiligung Multizentrische internationale Therapiestudien bei ANCA-assoziierten Vaskulitiden im Rahmen der europäischen Osteoporose, Knochenstoffwechsel bei Niereninsuffizienz Mitgliedschaften:
Deutsche Gesellschaft für Innere Medizin Deutsche Gesellschaft für Rheumatologie Europäische Gesellschaft für Rheumatologie (EULAR European Ligue against Rheumatism), Nephrologie (EDTA European Dialysis and Transplantation Association) Advisory Boards zur Entwicklung neuer Therapien für entzündliche Nierenerkrankungen Rhein Main Arbeitsgemeinschaft für Nephrologie (auch Mitglied im wissenschaftlichen Beirat) Ausgewählte Publikationen in chronologischer Reihenfolge
de Groot K, Schnabel A, Gross WL (1995) [ANCA-associated vasculitis (Wegener's granulomatosis, Churg- Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure]. Z Rheumatol 54(5): 291-302. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL (1995) Treatment of anti- neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101(1): 2-7. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, Gross WL (1996) Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 39(12): 2052-61. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL (1996) Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 89(1): Wang G, Csernok E, de Groot K, Gross WL (1997) Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods 208(2): 203-11. de Groot K, Gross WL (1998) Wegener's granulomatosis: disease course, assessment of activity and extent de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL (1998) Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 25(3): 492-5. de Groot K, Haubitz M, Haller H (2000) [ANCA-associated vasculitis. New concepts and strategies in therapy]. Internist (Berl) 41(10): 1112-9. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, Heller M, Gross WL (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43(5): 1021-32. 10. de Groot K, Adu D,Savage CO (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16(10): 2018-27. 11. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E (2001) Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 55(1): 31-8. 12. Reinhold-Keller E, de Groot K, Holl-Ulrich K, Arlt AC, Heller M, Feller AC, Gross WL (2001) Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp 13. De Groot K (2002) [Initial results of multicenter, randomized, controlled therapy studies of ANCA-associated 14. Haubitz M, de Groot K (2002) Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 57(6): 421-4. 15. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, de Groot K (2002) High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis 16. Woywodt A, Bahlmann FH, de Groot K, Haller H, Haubitz M (2002) Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrol Dial Transplant 17(10): 1728-30. 17. de Groot K (2003) [Initial results of multicenter, randomized, controlled therapy studies for ANCA-associated 18. de Groot K, Gross WL, Hellmich B (2003) [Therapy of primary systemic vasculitis]. Internist (Berl) 44(12): 19. De Groot K, Gross WL, Schnabel A (2003) [Pulmonary renal syndrome]. Internist (Berl) 44(9): 1140-50. 20. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349(1): 36-44. 21. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M (2003) Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361(9353): 206-10. 22. Bahlmann FH, de Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D (2004) Erythropoietin regulates endothelial progenitor cells. Blood 103(3): 921-6. 23. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E et al (2004) Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 24. Csernok E, Holle J, Hellmich B, Willem J, Tervaert C, Kallenberg CG, Limburg PC, Niles J, Pan G, Specks U et al (2004) Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology 25. de Groot K, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H,Fliser D (2004) Uremia causes endothelial progenitor cell deficiency. Kidney Int 66(2): 641-6. 26. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D (2005) Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45(4): 27. de Groot K, Bahlmann FH, Bahlmann E, Menne J, Haller H, Fliser D (2005) Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 79(8): 941-5. 28. de Groot K, Jayne D (2005) What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 64(6): 480-4. 29. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R,Jayne DR (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8): 2461-9. 30. de Groot K, Schnabel A (2005) [Pulmonary-renal syndrome]. Internist (Berl) 46(7): 769-81; quiz 782. 31. Haubitz M, Woywodt A, de Groot K, Haller H, Goebel U (2005) Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis. Ann Rheum Dis 64(10): 1500-2. 32. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D et al (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111(18): 2356-63. 33. Woywodt A, de Groot K, Bahte S, Schwarz A, Haller H, Haubitz M (2006) Severe relapse of Wegener's granulomatosis during the early postpartum period. Ann Rheum Dis 65(1): 137. 34. Woywodt A, Goldberg C, Kirsch T, de Groot K, Erdbruegger U, Haller H, Haubitz M (2006) Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis. Ann 35. de Groot K, Goldberg C, Bahlmann FH, Woywodt A, Haller H, Fliser D, Haubitz M (2007) Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 36. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66(3): 283-92. 37. Flossmann O, de Groot K (2007) When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy? Nat Clin Pract Nephrol 3(5): 236-7. 38. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, Gross WL, Reinhold-Keller E (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46(7): 1087-91. 39. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R (2008) Development of comprehensive disease assessment in systemic vasculitis. Postgrad Med J 84(989): 143- 40. Sunderkoetter C, de Groot K (2008) Therapie von Vaskulitiden und Vaskulopathien. Hautarzt 59: 382-393. 41. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10): 670- 42. de Groot K, Reinhold-Keller E (2009) [Wegener's granulomatosis and microscopic polyangiitis]. Z Rheumatol 43. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3): 310-7. 44. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann 45. Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, Brogan P, Calabrese L, Cid MC, Cohen-Tervaert JW et al (2010) EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69(10): 1744-50. 46. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, Hauser T, Neumann I, Tesar V, Wissing KM et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304(21): 2381-8. 47. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 48. Lorenzen J, David S, Bahlmann FH, de Groot K, Bahlmann E, Kielstein JT, Haller H, Fliser D (2010) Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease--a prospective 49. Reinhold-Keller E, de Groot K (2010) Use of methotrexate in ANCA-associated vasculitides. Clin Exp 50. de Groot K, Marker-Hermann E (2011) [Managing comorbidities of inflammatory rheumatic diseases]. 51. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3): 488-94. 52. Schonermarck U, de Groot K (2011) Vasculitis: Rituximab: effective in ANCA-associated vasculitis? Nat Rev 53. de Groot K (2012) Renal disease in small-vessel vasculitis. Cleve Clin J Med 79 Suppl 3: S22-6. 54. de Groot K (2012) Therapie ANCA-assoziierter Vaskulitiden - eine aktuelle Kurzübersicht. Nieren- und Hochdruckkrankheiten 41(4/2012): 166 -171. 55. de Groot K, Marker-Hermann E (2012) [Secondary vasculitides and vasculitis mimics]. Z Rheumatol 71(9): 56. Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Hoglund P, Jayne DR (2012) Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis 57. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA- associated vasculitis: long-term follow-up. Ann Rheum Dis 71(6): 955-60. 58. Hellmich B, de Groot K (2012) Kryoglobulinämische Vaskulitis. Der Nephrologe 7(3): 209 - 212. 59. Schönermarck U, Gross WL, de Groot K (2013) Treatment of ANCA-associated vasculitis. Nat Rev Nephrol. 2013 Nov 5. doi: 10.1038/nrneph.2013.225. [Epub ahead of print]

Source: http://www.kfh.de/fileadmin/synched_images/mitarbeiter/50025542.pdf

Wzorzec-przegl d lekarski-xx-200

5-fosfodiesterazy w leczeniu zaburzeñ erekcjiu pacjentów z chorobami uk³adu kr¹¿eniaThe safety of 5-phoshodiesterase inhibitorsin the treatment of erectile dysfunction in patientsI Klinika Kardiologii i Nadciœnienia Têtniczego,cym niekorzystnie na jakoœæ ¿ycia. Ordynator: Dr hab. med. Marek Wyczó³kowskiczêœciej u¿ywan¹ klas¹ leków w lecze-zym, który hamuj¹ znajduje siê

Addendum instr.indd

ADDITIONAL INSTRUCTIONS 2.1 Check Brake Lines at hub 2.1.1 ChildPod® Rear Wheels may not install due to Brake Arm engagement during shipment 1. Remove Steering Limiter Bolt During shipping, the Brake Arm may engage and push the Cable Housing out of its Barrel Adjustor. End of Cable Housing must insert fully into its Barrel Adjustor to 20 mm or equivalent wrench required. 1. Steerin

Copyright © 2010-2014 Articles Finder